Intact Investment Management Inc. Increases Holdings in Bausch Health Companies Inc. (NYSE:BHC)

Intact Investment Management Inc. grew its holdings in shares of Bausch Health Companies Inc. (NYSE:BHC) by 38.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 261,300 shares of the company’s stock after purchasing an additional 72,300 shares during the quarter. Intact Investment Management Inc.’s holdings in Bausch Health Companies were worth $2,112,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. CIBC Asset Management Inc increased its position in shares of Bausch Health Companies by 0.3% during the 3rd quarter. CIBC Asset Management Inc now owns 374,729 shares of the company’s stock valued at $3,060,000 after purchasing an additional 1,082 shares during the last quarter. Tobam increased its position in shares of Bausch Health Companies by 10.4% during the 4th quarter. Tobam now owns 15,034 shares of the company’s stock valued at $121,000 after purchasing an additional 1,422 shares during the last quarter. Northwest & Ethical Investments L.P. increased its position in shares of Bausch Health Companies by 13.0% during the 3rd quarter. Northwest & Ethical Investments L.P. now owns 32,384 shares of the company’s stock valued at $264,000 after purchasing an additional 3,734 shares during the last quarter. Sanders Morris Harris LLC increased its position in shares of Bausch Health Companies by 16.0% during the 4th quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company’s stock valued at $234,000 after purchasing an additional 4,000 shares during the last quarter. Finally, Kendall Capital Management increased its position in shares of Bausch Health Companies by 43.4% during the 4th quarter. Kendall Capital Management now owns 17,995 shares of the company’s stock valued at $145,000 after purchasing an additional 5,445 shares during the last quarter. 78.65% of the stock is owned by hedge funds and other institutional investors.

Bausch Health Companies Stock Up 3.7 %

Shares of NYSE BHC opened at $7.15 on Friday. Bausch Health Companies Inc. has a 52 week low of $3.96 and a 52 week high of $11.46. The business has a 50-day simple moving average of $7.22 and a two-hundred day simple moving average of $7.63. The company has a market cap of $2.63 billion, a P/E ratio of -59.54, a P/E/G ratio of 0.37 and a beta of 0.59.

Bausch Health Companies (NYSE:BHC) last issued its earnings results on Wednesday, February 19th. The company reported $1.21 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.44). Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. The company had revenue of $2.56 billion during the quarter, compared to the consensus estimate of $2.51 billion. Equities research analysts anticipate that Bausch Health Companies Inc. will post 4.41 EPS for the current year.

Analysts Set New Price Targets

BHC has been the subject of several recent research reports. Royal Bank of Canada decreased their price objective on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating for the company in a report on Thursday, January 30th. Jefferies Financial Group reissued a “hold” rating and issued a $8.00 price objective (down previously from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. One analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $7.42.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.